Victory Capital Management Inc. acquired a new position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX – Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 41,240 shares of the company’s stock, valued at approximately $953,000. Victory Capital Management Inc. owned 0.07% of SpringWorks Therapeutics as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. raised its stake in SpringWorks Therapeutics by 96.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 1,612 shares of the company’s stock valued at $37,000 after purchasing an additional 792 shares during the period. IFP Advisors Inc grew its holdings in SpringWorks Therapeutics by 31.2% during the 2nd quarter. IFP Advisors Inc now owns 2,794 shares of the company’s stock valued at $63,000 after buying an additional 665 shares in the last quarter. Osaic Holdings Inc. grew its holdings in SpringWorks Therapeutics by 42.8% during the 2nd quarter. Osaic Holdings Inc. now owns 2,609 shares of the company’s stock valued at $69,000 after buying an additional 782 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in SpringWorks Therapeutics by 64.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 3,122 shares of the company’s stock valued at $82,000 after buying an additional 1,222 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY grew its holdings in SpringWorks Therapeutics by 65.3% during the 2nd quarter. Metropolitan Life Insurance Co NY now owns 3,185 shares of the company’s stock valued at $84,000 after buying an additional 1,258 shares in the last quarter.
SpringWorks Therapeutics Stock Down 2.2 %
SWTX opened at $45.91 on Tuesday. The business has a fifty day moving average of $38.88 and a 200 day moving average of $29.96. SpringWorks Therapeutics, Inc. has a 52-week low of $18.00 and a 52-week high of $49.98. The stock has a market cap of $2.87 billion, a P/E ratio of -9.39 and a beta of 0.82.
Wall Street Analysts Forecast Growth
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors.
- Five stocks we like better than SpringWorks Therapeutics
- Investing in Vaccines 101: How to Invest in Vaccine Stocks
- 3 attractive stocks that insiders are buying
- Stocks in the Dow: About the Dow Jones Industrial Average (DJIA)
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.